Mandate

Vinge advises Industrifonden in connection with its investment in InDex Pharmaceuticals

January 24, 2011

Vinge has advised Industrifonden in connection with its SEK 40 million investment in InDex Pharmaceuticals. InDex Pharmaceuticals develops Kappaproct, a drug developed for the treatment of severe inflammatory bowel disease. Further capital has also been raised from current shareholders, including SEB Venture Capital, which has invested an additional SEK 35 million. The financing will predominantly be used to conduct a clinical phase III trial using Kappaproct with the aim of obtaining market approval.

Vinge’s team consisted of, among others, project manager Johan Larsson and Petter Kjöllerström, who was responsible for the due diligence phase of the transaction. Johan Winnerblad was the responsible partner.

Related

Vinge advises Lagercrantz Group in conjunction with the acquisition of Stalon

Lagercrantz Group Aktiebolag has acquired 88 per cent of the shares in Stalon AB, a Swedish manufacturer of silencers for hunting firearms. The company is based in Stalon, which is located outside Vilhelmina, where the company conducts development and production in its own facilities.
May 21, 2026

Vinge advises PPI Public Property Invest AB (publ) in connection with cross-border merger and listing on Nasdaq Stockholm and Euronext Oslo Børs

Vinge has advised PPI Public Property Invest AB (publ) (“PPI”) in connection with its listing on Nasdaq Stockholm and secondary listing on Euronext Oslo Børs. The listing was carried out through a cross-border merger whereby PPI absorbed Public Property Invest ASA, whose shares were previously listed on Euronext Oslo Børs.
May 20, 2026

Vinge represents Triton in connection with the sale of Aleris

Vinge has represented Triton in connection with the sale of Aleris to Mehiläinen Group.
May 18, 2026